Have a feature idea you'd love to see implemented?
Let us know!
ARVN Arvinas Inc
Price (delayed)
$18.48
Market cap
$1.27B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.79
Enterprise value
$1.19B
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing
Highlights
Arvinas's revenue has soared by 73% from the previous quarter
The gross profit has soared by 73% from the previous quarter
The company's equity rose by 28% YoY but it fell by 2.4% QoQ
The company's net income rose by 4.6% QoQ but it fell by 4.5% YoY
Key stats
What are the main financial stats of ARVN
Market
Valuations
Earnings
Shares outstanding
68.71M
Market cap
$1.27B
Enterprise value
$1.19B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.16
Price to sales (P/S)
8.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.36
Revenue
$161.1M
Gross profit
$161.1M
Net income
-$308.6M
EBIT
-$306.1M
EBITDA
-$299.4M
Free cash flow
-$259.8M
Per share
Balance sheet
Liquidity
EPS
-$4.79
EPS diluted
-$4.79
Free cash flow per share
-$3.6
Book value per share
$8.54
Revenue per share
$2.23
TBVPS
$16.19
Total assets
$1.17B
Total liabilities
$581.1M
Debt
$1.5M
Equity
$586M
Working capital
$873.6M
Debt to equity
0
Current ratio
4.17
Quick ratio
4.12
Net debt/EBITDA
0.28
Margins
Efficiency
Dividend
EBITDA margin
-185.8%
Gross margin
100%
Net margin
-191.6%
Operating margin
-221.8%
Return on assets
-24.9%
Return on equity
-50.3%
Return on invested capital
-38.3%
Return on capital employed
-34.3%
Return on sales
-190%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARVN stock price
How has the Arvinas stock price performed over time
Intraday
3.65%
1 week
-5.23%
1 month
-18.55%
1 year
-49.3%
YTD
-55.1%
QTD
-24.97%
Financial performance
How have Arvinas's revenue and profit performed over time
Revenue
$161.1M
Gross profit
$161.1M
Operating income
-$357.4M
Net income
-$308.6M
Gross margin
100%
Net margin
-191.6%
Arvinas's revenue has soared by 73% from the previous quarter
The gross profit has soared by 73% from the previous quarter
The net margin rose by 45% since the previous quarter but it has declined by 3.4% year-on-year
Arvinas's operating margin has increased by 44% from the previous quarter but it has decreased by 13% YoY
Growth
What is Arvinas's growth rate over time
Valuation
What is Arvinas stock price valuation
P/E
N/A
P/B
2.16
P/S
8.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.36
The EPS has grown by 13% YoY and by 9% from the previous quarter
The stock's price to book (P/B) is 52% less than its 5-year quarterly average of 4.5 and 38% less than its last 4 quarters average of 3.5
The company's equity rose by 28% YoY but it fell by 2.4% QoQ
The P/S is 83% below the 5-year quarterly average of 50.0 and 68% below the last 4 quarters average of 25.5
Arvinas's revenue has soared by 73% from the previous quarter
Efficiency
How efficient is Arvinas business performance
The ROS has grown by 45% from the previous quarter but it has contracted by 6% YoY
ARVN's return on equity is up by 15% year-on-year and by 10% since the previous quarter
The company's return on invested capital rose by 10% QoQ
ARVN's return on assets is up by 6% since the previous quarter and by 3.5% year-on-year
Dividends
What is ARVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARVN.
Financial health
How did Arvinas financials performed over time
ARVN's total assets is 101% more than its total liabilities
The quick ratio is up by 28% year-on-year and by 15% since the previous quarter
ARVN's current ratio is up by 28% YoY and by 15% QoQ
The debt is 100% smaller than the equity
The debt to equity has plunged by 100% YoY
The debt has dropped by 63% year-on-year and by 29% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.